Description
Introduction
Sturge-Weber syndrome (SWS) is a neurological disorder that is present at birth. The affected individual has a noticeable distinctive port-wine stain on the forehead, scalp, or around the eye. This stain is a birthmark caused by a blood vessel abnormality. A large number of people with SWS also suffers from seizures or convulsions. Sturge-Weber syndrome develops a blood vessel abnormality called leptomeningeal angiomas in the brain. Other features of this SWS syndrome include glaucoma, paralysis, developmental delay, and intellectual disability. The person suffering from this may also have other complications such as increased pressure in the eye, developmental delays, and weakness on one side of the body. However, the factors responsible for market growth include technological advancements, increasing awareness among people, and increasing government assistance.
However, increasing challenges in research and development, the high cost of treatment, and poor healthcare system may hamper the market growth.
The global sturge-weber syndrome market has been segmented by type, diagnosis and treatment, and end user.
The global sturge-weber syndrome market has been divided, by type into type 1, type 2 and type 3.
Based on diagnosis and treatment, the global sturge-weber syndrome market has been categorized into diagnosis and treatment.
On the basis of end user, the market has been classified as hospitals and clinics and diagnostic centers.
The global sturge-weber syndrome market was valued at USD 2277.4 million in 2017 and is expected to register a CAGR of 5.3 % during the forecast period from 2018 to 2023.
Key Players
Some of the key players in the global sturge-weber syndrome market are Abbott, Pfizer Inc, F. Hoffmann-La Roche AG, Novartis AG, UCB SA, Sanofi, Shire, Aleva Neurotherapeutics SA, GW Pharmaceuticals, PLC, ElectroCore LLC, and Johnson & Johnson.
Objectives of the Study
? To provide a detailed analysis of the market structure along with a forecast of various segments and sub-segments of the global sturge-weber syndrome market
? To provide insights into factors influencing and affecting market growth
? To provide historical and forecast revenue of market segments and sub-segments with respect to countries
? To provide strategic profiling of key players in the market and comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market
? To provide economic factors that influence the global sturge-weber syndrome market
? To provide a detailed analysis of the value chain and supply chain of the global sturge-weber syndrome market
Target Audience
? Potential Investors
? Associations
? Government Research Institutes
? End Users
? Raw Material Suppliers
? Drugs Suppliers and Manufacturers
Key Findings
? The global sturge-weber syndrome market is expected to reach USD 2277.4 million by 2023 at a CAGR of 5.3 % from 2018 to 2023.
? On the basis of type, the type 1 segment accounted for the largest market share of 47.44% in 2017 and is expected to be USD 792.6 million by 2023.
? The market in the Americas is expected to account for the largest share of the global sturge-weber syndrome market and is projected to reach USD 812.2 million by 2023.
? The market in Asia-Pacific is projected to be the fastest growing at a CAGR of 5.9 % from 2018 to 2023.
Regional Analysis
? Americas
o North America
? US
? Canada
o Latin America
? Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
? Asia-Pacific
o Japan
o China
o India
o Australia
o South Korea
o Rest of Asia-Pacific
? Middle East & Africa
o Middle East
o Africa
Table of Contents
Table of Contents:
1 Report Prologue
2 Executive Summary
3 Market Introduction
3.1 Definition
3.2 Scope of the Study
3.3 Assumptions & Limitations
3.3.1 Assumptions
3.3.2 Limitations
3.4 Market Structure
4 Research Methodology
4.1 Research Process
4.1 Primary Research
4.2 Secondary Research
4.3 Market Size Estimation
4.4 Forecast Model
5 Market Dynamics
5.1 Introduction
5.2 Drivers
5.2.1 The increasing prevalence of epilepsy and glaucoma
5.2.2 Rising research and development funding for rare diseases
5.2.3 Increasing focus on players towards Sturge-weber syndrome
5.3 Restraints
5.3.1 Side effects of therapeutic drugs
5.4 Opportunities
5.4.1 Rising demand for non-invasive treatment generating requirement for laser therapy
5.5 Macroeconomic Indicators
6 Market Factor Analysis
6.1 Supply Chain Analysis
6.1.1 R&D
6.1.2 Parts Manufacturing
6.1.3 Distribution
6.1.4 Marketing & Sales
6.1.5 Post-Sales Monitoring
6.2 Demand & Supply: Gap Analysis
6.3 Pricing Analysis
6.4 Investment Opportunities
6.5 Porter’s Five Forces Model
6.5.1 Bargaining Power of Suppliers
6.5.2 Bargaining Power of Buyers
6.5.3 Threat of New Entrants
6.5.4 Threat of Substitutes
6.5.5 Intensity of Rivalry
7 Global Sturge-Weber Syndrome Market, by Type
7.1 Overview
7.1.1 Type 1
7.1.2 Type 2
7.1.3 Type 3
8 Global Sturge-Weber Syndrome Market, by Diagnosis & Treatment
8.1 Overview
8.1.1 Treatment
8.1.2 Diagnosis
9 Global Sturge-Weber Syndrome Market, By End-User
9.1 Overview
9.1.1 Hospital & Clinics
9.1.2 Diagnostic Centre
10 Sturge-Weber Syndrome Market, by Region
10.1 Introduction
10.2 Americas
10.2.1 North America
10.2.1.1 U.S.
10.2.1.2 Canada
10.2.2 South America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 U.K
10.3.1.4 Italy
10.3.1.5 Spain
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 Republic of Korea
10.4.6 Rest of Asia Pacific
10.5 The Middle East and Africa
10.5.1 Middle East
10.5.2 Africa
11 Competitive Landscape
11.1 Company Market Share Analysis
11.1.1 Introduction
11.2 Competitive Landscape
11.2.1 Introduction
11.3 Key Developments
12 Company Profiles
12.1 Abbott
12.1.1 Company Overview
12.1.2 Financial Overview
12.1.3 Products Offerings
12.1.4 Key Developments
12.1.5 SWOT Analysis
12.1.6 Key Strategy
12.2 Pfizer Inc.
12.2.1 Company Overview
12.2.2 Financial Overview
12.2.3 Products Offerings
12.2.4 Key Developments
12.2.5 SWOT Analysis
12.2.6 Key Strategy
12.3 F. Hoffmann-La Roche AG
12.3.1 Company Overview
12.3.2 Financial Overview
12.3.3 Products Offerings
12.3.4 Key Developments
12.3.5 SWOT Analysis
12.3.6 Key Strategy
12.4 Novartis AG
12.4.1 Company Overview
12.4.2 Financial Overview
12.4.3 Products Offerings
12.4.4 Key Developments
12.4.5 SWOT Analysis
12.4.6 Key Strategy
12.5 UCB S.A.
12.5.1 Company Overview
12.5.2 Financial Overview
12.5.3 Products Offerings
12.5.4 Key Developments
12.5.5 SWOT Analysis
12.5.6 Key Strategy
12.6 Sanofi
12.6.1 Company Overview
12.6.2 Financial Overview
12.6.3 Products Offerings
12.6.4 Key Developments
12.6.5 SWOT Analysis
12.6.6 Key Strategy
12.7 Shire
12.7.1 Company Overview
12.7.2 Financial Overview
12.7.3 Products Offerings
12.7.4 Key Developments
12.7.5 SWOT Analysis
12.7.6 Key Strategy
12.8 Aleva Neurotherapeutics SA
12.8.1 Company Overview
12.8.2 Products Offering
12.8.3 Key Developments
12.8.4 SWOT Analysis
12.8.5 Key Strategy
12.9 GW Pharmaceuticals, plc.
12.9.1 Company Overview
12.9.2 Financial Overview
12.9.3 Products Offerings
12.9.4 Key Developments
12.9.5 SWOT Analysis
12.9.6 Key Strategy
12.1 ElectroCore LLC
12.10.1 Company Overview
12.10.2 Products Offerings
12.10.3 Key Developments
12.10.4 SWOT Analysis
12.10.5 Key Strategy
12.11 Johnson & Johnson
12.11.1 Company Overview
12.11.2 Financial Overview
12.11.3 Products Offerings
12.11.4 Key Developments
12.11.5 SWOT Analysis
12.11.6 Key Strategy
13 Appendix
13.1 Discussion Blue Print
13.2 References
